研究单位：[1]Department of Infectious Disease,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China感染科[2]Guangshui First Peoples Hospital,Guangshui,Hubei,China[3]Huanggang Central Hospital,Huanggang,Hubei,China[4]Luotian County Peoples Hospital,Huanggang,Hubei,China[5]Macheng Peoples Hospital,Macheng,Hubei,China[6]Qianjiang Central Hospital,Qianjiang,Hubei,China[7]Suizhou Central Hospital,Suizhou,Hubei,China[8]Xianning Central Hospital,Xianning,Hubei,China[9]Yichang Third Peoples Hospital,Yichang,Hubei,China[10]Jiangsu Province Hospital,Nanjing,Jiangsu,China
This is a prospective, multicenter, non-randomized, controlled intervention clinical study.Patients with severe fever with thrombocytopenia syndrome who have been clinically diagnosed and met the study inclusion criteria will be included in the study for analysis. All patients with SFTS will be assigned to different groups according to the ratio of 1:3, including the non-intervention group (conventional treatment group) and the related drug intervention group. Non-intervention group:patients received standard care during hospitalization. Intervention group: Part A group: Patients received methylprednisolone 2mg/kg/d + intravenous immunoglobulin (IVIG) 20g/d for a total of 5 days. If the disease progressed after treatment, the patients was given the dose of rescue therapy (methylprednisolone > 2mg/kg/d + IVIG 20g/d) for another 5 days. Part B group: Patients received tocilizumab 4mg/kg once. Part C group: Patients received low molecular weight heparin 100U/kg, q12h IH for 7 days. All patients were followed up from the end of treatment to day 28 after completion of treatment.
